In vitro fertilization (IVF) is a series of procedures used to treat infertility or genetic problems, and assist with the conception of a child. During IVF, mature eggs are collected from the ovaries and fertilized by sperm in a laboratory. The embryos or eggs are then implanted in the uterus. The IVF process includes various fertility medications, medical devices, surgeries, or a combination of all.

The global in vitro fertilization market is projected to reach USD 847.83 Million by 2022 from USD 505.15 Million in 2017, at a CAGR of 10.9%. The key factors propelling the growth of this market include growth in the median age of first-time motherhood, declining fertility rates, rising male infertility, rise in consumption of alcohol and cigarettes, and growing public awareness about infertility and the available treatment options.

By product, the in vitro fertilization market is categorized into reagents and equipment. Reagents are further segmented into cryopreservation media, semen processing media, ovum processing media, and embryo culture media. Embryo culture media is expected to hold the largest share of the IVF reagents market and is also projected to grow at the highest rate during the forecast period. The large share of this segment is attributed to the increase in awareness of infertility treatment and diagnosis.

The equipment segment is further classified into imaging systems, sperm separation systems, cabinets (workstations), ovum aspiration pumps, incubators, micromanipulator systems, cryosystems, gas analyzers, laser analyzers, anti-vibration tables, accessories, and witness systems. However, sperm separation systems are expected to witness the highest growth, due to factors such as the rising use of donated sperm in IVF procedures.

On the basis of end users, the global IVF market has been segmented into fertility clinics and surgical centers, hospitals and research laboratories, and cryobanks. The fertility clinics and surgical centers segment is estimated to command the largest share of the global market in 2017. This segment is also projected to register the highest CAGR during the forecast period. The increasing number of fertility centers coupled with the growing infertility rates across the globe are the key factors driving the growth of the fertility and surgical centers segment.

On the basis of types of cycles, the in vitro fertilization market is segmented into fresh non-donor, frozen non-donor, fresh donor, and frozen donor. Fresh non-donor is expected to account for the largest share in 2017. Factors such as high success rate, ease in implantation process and enhanced embryo production are driving the growth for the fresh non-donor market. However, the frozen non-donor cycle segment is projected to register the highest growth rate during the forecast period.

Geographically, the in vitro fertilization market in Asia Pacific accounts for the largest share of the global market, followed by Europe. The large share and high growth rate of the APAC region can be attributed growth in the median age of first-time motherhood, rising infertility rates, growing prevalence of PCOS, increasing incidence of obesity, rise in fertility tourism, and government initiatives.

However, the high cost of the procedure and restrictive regulations and ethical concerns is likely to restrain the growth of the market during the forecast period.

CooperSurgical (US), Vitrolife (Sweden), Cook Medical (US), Irvine Scientific (US), and Thermo Fisher Scientific (US) are the key players in the in vitro fertilization market. Other players include EMD Sereno (US), Genea Limited (Australia), Esco Micro (Singapore), IVFtech (Denmark), Rocket Medical (UK), Nidacon International (Sweden), Lotus Bio (Israel), Eppendorf (Germany), Okolab (Italy), IKS International (Netherlands), Hunter Scientific (UK), Thomas Medical (US), Labotect (Germany), Shivani Scientific (India), Olympus Corporation (Japan), and RI.MOS. (Italy).

Innovators are players that have demonstrated substantial product innovations as compared to their competitors. They have innovative products and the potential to develop strong strategies for their business growth to be at par with the visionary leaders. EMD Sereno Inc. (US), Labotect GmbH (Germany), BIOGENICS, INC. (US), RI.MOS.srl (Italy), and Eppendorf AG (Germany) are considered as the innovators of this market.